Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.

• Authors: HLAVÁČ Kryštof; ONDRIŠOVÁ Laura; ŠEDA Václav; HOFERKOVÁ Eva; CHIODIN G.; KOŠŤÁLOVÁ Lenka; MLADONICKÁ PAVLASOVÁ Gabriela; FILIP Daniel; FARIA ZENI Pedro; OPPELT Jan; PANOVSKÁ Anna; PLEVOVÁ Karla; POSPÍŠILOVÁ Šárka; ŠIMKOVIČ M.; VRBACKÝ F.; LYSÁK Daniel; FERNANDES SM.; DAVIDS MS.; MAIQUES-DIAZ A.; CHARALAMPOPOULOU S.; MARTIN-SUBERO I.; BROWN JR.; DOUBEK Michael; FORCONI Francesco; MAYER Jiří; MRÁZ Marek
• Year of publication: 2023
• Type: Conference abstract
• MU Faculty or unit: Central European Institute of Technology

Attached files

• cacr23_abstrakta_web_2.pdf

• Description: Genetic resistance mechanisms to BCR inhibitors in CLL have been extensively described, but it remains unclear whether non-genetic adaptation might exist in CLL cells allowing for lasting lymphocytosis or resistance. We focused on the possible role of the Akt pathway in adapting to BCR inhibitors since, in mouse models, PI3K-Akt activation is the only known factor that rescues the apoptosis induced by BCR deletion in mature B cells.

Related projects

• ÚLOHA MICRORNA A JEJICH CÍLOVÝCH MOLEKUL V TRANSFORMACI FOLIKULÁRNÍHO LYMFOMU A AGRESIVITĚ CHRONICKÉ LYMFOCYTÁRNÍ LEUKÉMIE
• Signaling propensity in the microenvironment of B cell chronic lymphocytic leukemia
• National institute for cancer research
• Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit X